Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the
“Company”), a biotechnology company focused on progressing
psychedelic therapeutics, today announced that it has signed a drug
development agreement with Catalent, Inc. (NYSE:CTLT) the leading
global provider of advanced delivery technologies, development, and
manufacturing solutions for drugs, biologics, cell and gene
therapies, and consumer health products.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210322005181/en/
Cybin will be applying Catalent’s proprietary Zydis® orally
disintegrating tablet (ODT) technology for the delivery of our
novel deuterated tryptamine (CYB003), a potential therapy for
treatment-resistant psychiatric disorders.
Zydis technology creates a freeze-dried tablet that disperses
almost instantly in the mouth without water and is recognized as
one of the world’s best-performing ODTs. Delivering CYB003 in such
a dose form could have significant benefits, as an ODT would allow
pre-gastric delivery and prevent first pass metabolism, potentially
improving the pharmacokinetic profile of the drug. The project is
due to commence in April 2021 and will involve initial feasibility
studies being conducted for the manufacturing and analytical
testing of ODT doses containing varying quantities of CYB003,
alongside different excipients.
Catalent’s 250,000 sq. ft. site in Swindon, U.K. houses the
company’s Zydis development and manufacturing operation, which
produces over one billion ODTs annually.
Jonathan Arnold, President of Oral and Specialty Delivery at
Catalent, commented, “We look forward to working with Cybin to
potentially develop a novel and fast-acting therapy for
treatment-resistant psychiatric disorders. The Zydis platform is an
ideal technology to leverage for this type of drug formulation, as
pre-gastric absorption is crucial for efficacy.”
Doug Drysdale, Cybin’s CEO, added, “We are excited to partner
with the team at Catalent with the aim of developing fast-acting,
shorter-duration formulations of CYB003, recently acquired as part
of our acquisition of Adelia Therapeutics. Our focus on reducing
the need for health system resources, such as in-clinic therapist
time, is an important part of our goal to create scalable, more
accessible treatments for mental health disorders.”
About Catalent
Catalent is the leading global provider of advanced delivery
technologies, development, and manufacturing solutions for drugs,
biologics, cell and gene therapies, and consumer health products.
With over 85 years serving the industry, Catalent has proven
expertise in bringing more customer products to market faster,
enhancing product performance and ensuring reliable global clinical
and commercial product supply. Catalent employs around 15,000
people, including approximately 2,400 scientists and technicians,
at more than 45 facilities, and in fiscal year 2020 generated over
$3 billion in annual revenue. Catalent is headquartered in
Somerset, New Jersey. For more information, visit
www.catalent.com
More products. Better treatments. Reliably supplied.™
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “may”, “should”, “could”, “intend”,
“estimate”, “plan”, “anticipate”, “expect”, “believe” or
“continue”, or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding enhanced liquidity, the value of additional capital
markets exposure, access to institutional and retail investors, the
Company’s new strategic brand messaging campaign, and psychedelic
drug development programs to potentially treat mental health
disorders. There are numerous risks and uncertainties that could
cause actual results and Cybin’s plans and objectives to differ
materially from those expressed in the forward-looking information.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin’s proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products have not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin’s
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210322005181/en/
Investor Contacts: Tim Regan/Scott Eckstein KCSA
Strategic Communications Cybin@kcsa.com
Lisa M. Wilson In-Site Communications, Inc.
lwilson@insitecony.com
Media Contacts for Cybin: John Kanakis Cybin Inc.
John@cybin.com
Annie Graf KCSA Strategic Communications agraf@kcsa.com
Faith Pomeroy-Ward In-Site Communications, Inc.
Faith@insitecony.com
Media Contacts for Catalent: Richard Kerns +44 (0)161 728
5880 richard@nepr.agency
Chris Halling +44 (0)7580 041073 chris.halling@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Apr 2023 to Apr 2024